Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Feb 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how patients feel about their dry eye symptoms after receiving an injection of a medication called anti-VEGF, which is used to treat serious eye conditions like macular degeneration, diabetic macular edema, and retinal vein occlusion. The study aims to understand how these injections might affect the sensation of dry eyes in patients who have already had a few of these treatments.

To participate in this study, you need to be between 65 and 74 years old and have been diagnosed with one of the eye conditions mentioned. You should also have already received three anti-VEGF injections in one eye. Unfortunately, if you are pregnant, have had an injection in both eyes, or have certain allergies, you wouldn't be eligible to join. If you decide to take part, you will be asked to share your experience with dry eye symptoms, helping researchers understand the effects of these important injections better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with exsudative age-related macular degeneration, diabetic macular edema or retinal vein occlusion
• • Patient with 3 ocular intravitreal injections of anti-VEGF in one eye
• Exclusion Criteria:
• • pregnant or breastfeeding woman
• • intravitreal injection before the study
• • intravitreal injection in both eyes
• • allergy of betadine
• • guardianship patient